Prostamax

updated

Prostamax is the synthetic tetrapeptide Lys-Glu-Asp-Pro from the Khavinson group of Russian short-peptide bioregulators, sold for prostate support. No human study exists. Its only prostate result is faster growth of rat prostate explants in culture, the rest is chromatin measures in human blood cells, and there is no prostate disease model, no prostate measure in any living animal and no human dose. Prostatilen, a cattle prostate extract with clinical reports of its own, is a different product.

Synthetic tetrapeptide bioregulator

  • PubChem lists Prostamax as CID 9848296, C20H33N5O9, molecular weight 487.5, CAS 473578-47-1, with a name that reads Lys-Glu-Asp-Pro. The group's 2022 table spells it Prostomax (KEDP).
  • Naming warning: Prostatilen, a cattle prostate extract with its own clinical reports, and Prostataget (DR), a dipeptide, are different products from this tetrapeptide.
  • The one study of the peptide in prostate tissue is a 2006 Russian-language report in which 0.05 ng/ml stimulated growth of prostate explants from 3-week-old and 18-month-old rats; it reports no prostate size, hormone or disease endpoint.
  • Four papers measured chromatin or chromosome changes in human blood cells in culture, none of them a prostate measure or a treatment of a person.
  • A PubMed search on 10 October 2026 for prostamax or prostomax returned 5 records: the explant study and four human-cell chromatin papers.
  • The same search with prostate terms returned 1 record, the explant study, and with clinical trial or randomized controlled trial publication types returned 0 records.

What is Prostamax, and is it an approved drug?

Prostamax is the synthetic tetrapeptide Lys-Glu-Asp-Pro (KEDP) from the Khavinson group, which the group's 2022 table spells Prostomax. openFDA Drugs@FDA and DailyMed return no product named Prostamax and ClinicalTrials.gov returned no study, so no FDA record was found.

PubChem lists Prostamax as CID 9848296, C20H33N5O9, molecular weight 487.5, CAS 473578-47-1, with a systematic name that reads Lys-Glu-Asp-Pro. The same sequence appears in a 2012 abstract about the oligopeptide bioregulator Prostamax (Lys-Glu-Asp-Pro), and the group's 2022 table lists Prostomax (KEDP) for regulation of prostatic functions and cites a European patent.

On 10 October 2026 openFDA Drugs@FDA and DailyMed returned no product named Prostamax, and ClinicalTrials.gov returned no study for Prostamax or for a KEDP prostate peptide. That covers FDA and registry sources and says nothing about other regulators.

PubChem: Prostamax identity

Chemical identity record

National Library of Medicine. PubChem compound record CID 9848296.

PubChem lists Prostamax as CID 9848296, C20H33N5O9, molecular weight 487.5, CAS 473578-47-1, with a systematic name that reads Lys-Glu-Asp-Pro. The same sequence appears in a 2012 abstract about the oligopeptide bioregulator Prostamax (Lys-Glu-Asp-Pro, PMID 23221144), and the group's 2022 table lists Prostomax (KEDP) for regulation of prostatic functions and cites a European patent.

Participants / model
Chemical identity, not a clinical population
Treatment
Defined synthetic peptide
Follow-up
Not applicable
Study design
NLM chemical record
Funding
not stated in the source

A defined tetrapeptide record.

Read the original source
PubMed: 5 records, one in prostate tissue, no clinical trial

PubMed search record

PubMed searches run 10 October 2026: prostamax[tiab] OR prostomax[tiab]; (prostamax OR prostomax OR "Lys-Glu-Asp-Pro" OR KEDP) AND (prostate OR prostatic OR BPH OR prostatitis OR hyperplasia); the same query with clinical trial or randomized controlled trial publication types. ClinicalTrials.gov, openFDA Drugs@FDA and DailyMed queries, run the same day.

A PubMed search for prostamax[tiab] OR prostomax[tiab] returned 5 records: the 2006 explant study and the four human-cell chromatin papers. A search for (prostamax OR prostomax OR "Lys-Glu-Asp-Pro" OR KEDP) AND (prostate OR prostatic OR BPH OR prostatitis OR hyperplasia) returned 1 record, the explant study. The same query with clinical trial or randomized controlled trial publication types returned 0 records. ClinicalTrials.gov returned no study for Prostamax or for a KEDP prostate peptide. openFDA Drugs@FDA and DailyMed return no product named Prostamax. In the records reviewed there is no animal model of prostate disease, no measure of prostate size, PSA, or urinary function after the peptide, no human dose, no human pharmacokinetics, and no human safety data.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Search run on 10 October 2026
Study design
Dated literature and registry search
Funding
not stated in the source

An absence finding as of 10 October 2026, not proof that no unpublished work exists.

Read the original source

Which similar names are not Prostamax?

The group's 2022 table spells the peptide Prostomax, and lists a different prostate peptide, Prostataget (DR), a dipeptide. Prostatilen, a polypeptide preparation from cattle prostate with clinical reports of its own, is a different product. Results for Prostatilen are not evidence about Prostamax.

The group's 2022 table spells the peptide Prostomax, while the abstracts spell it Prostamax. None of the 5 PubMed records for the peptide uses the Prostomax spelling, so it appears to be a table spelling only. Searching under both spellings finds the same peptide.

The same table lists a different prostate peptide, Prostataget (DR), a dipeptide. It is not Prostamax.

Naming warning: Prostatilen is a polypeptide preparation isolated from cattle prostate, a different product from the synthetic tetrapeptide. Its 1991 Russian-language clinical reports list Khavinson as an author and are open reports, with no placebo, comparison group or blinding described in the abstracts. They are results for the extract and are not evidence about Prostamax, so they are not described or used on this page.

2022 table: spelling Prostomax, and a different prostate dipeptide, Prostataget

Narrative review

Khavinson V et al. Int J Mol Sci. 2022;23(14). PMID 35887081.

The group's 2022 table spells the peptide Prostomax; the abstracts spell it Prostamax. The same table lists a different prostate peptide, Prostataget (DR), a dipeptide. None of the 5 records returned by the search below uses the Prostomax spelling, so it appears to be a table spelling only. Prostatilen, which has clinical papers of its own, is a different product.

Participants / model
Not a clinical population
Treatment
Not applicable
Follow-up
Not applicable
Study design
Review table
Funding
not stated in the source

Naming warning only. Prostatilen is a polypeptide preparation isolated from cattle prostate, and its 1991 Russian-language clinical reports (PMID 1823682, PMID 1823683, PMID 2058122) are for that extract, not for the synthetic tetrapeptide. Those reports are not evidence about Prostamax and are not described on this page.

Read the original source

What did the rat explant and blood cell studies find?

At 0.05 ng/ml the peptide stimulated growth of prostate explants from young and aged rats in culture, the only study of it in prostate tissue, with no prostate size, hormone or disease endpoint. Four other papers describe chromatin changes in human blood cells in culture, which are not prostate measures.

A 2006 Russian-language report used synthetic cardiogen, bronchogen, prostamax and pancragen on organotypic explants of heart, lung, prostate and pancreas from 3-week-old and 18-month-old rats. At 0.05 ng/ml each peptide stimulated growth in its matching tissue culture compared with control explants in all groups. The abstract reports no prostate size, hormone or disease endpoint. This is the only study of the peptide in prostate tissue, and growth of prostate tissue in culture is not a benefit endpoint.

A 2004 abstract found that Prostamax, with Epithalon and Livagen, decondensed pericentromeric chromatin of chromosome 1 in leukocytes from subjects aged 75 to 88. A 2004 Russian-language study found that prostamax shifted chromatin denaturation endotherms of human lymphocytes by 2.9 and 1.0 degrees C. A 2009 report combined it with copper and cadmium ions in lymphocyte culture.

A 2012 Russian-language study in cells from people aged 75 to 86 reports that Prostamax raised the sister chromatid exchange frequency to 12.0 per cell from 5.9 in untreated cells, raised Ag-positive nucleolus organizer regions to 2.5 per cell from 0.95, and reduced large pericentromeric heterochromatin variants on chromosomes 1 and 9; the authors read this as chromatin decondensation. These are chromatin measures in blood cells, not prostate measures, and no person was treated. The cell source and peptide concentration for this study are not stated here.

2006 explant study: prostate explants from young and aged rats

Cell study

Zakutskiĭ AN et al. Adv Gerontol. 2006;19:93-6. PMID 17152728.

A 2006 Russian-language report used synthetic cardiogen, bronchogen, prostamax, and pancragen on organotypic explants of heart, lung, prostate, and pancreas from 3-week-old and 18-month-old rats. At 0.05 ng/ml each peptide stimulated growth in its matching tissue culture compared with control explants in all groups. The abstract reports no prostate size, hormone, or disease endpoint. This is the only study of the peptide in prostate tissue, and growth of prostate tissue in culture is not a benefit endpoint.

Participants / model
Prostate explants from young (3-week) and aged (18-month) rats
Treatment
Peptide in culture medium at 0.05 ng/ml
Follow-up
not stated in the source
Study design
Organotypic explant culture, Russian-language report
Funding
not stated in the source

Explant growth is not a benefit endpoint, and the abstract reports no prostate size, hormone or disease measure.

Read the original source
Human blood cells in culture: chromatin decondensation and sister chromatid exchange

Cell study

Dzhokhadze TA et al. Georgian Med News. 2012(212):76-82. PMID 23221144.

A 2004 abstract found that Prostamax, with Epithalon and Livagen, decondensed pericentromeric chromatin of chromosome 1 in leukocytes from subjects aged 75 to 88 (PMID 15085253). A 2004 Russian-language study found that prostamax shifted chromatin denaturation endotherms of human lymphocytes by 2.9 and 1.0 degrees C (PMID 15612551). A 2012 Russian-language study in cells from people aged 75 to 86 reports that Prostamax raised the sister chromatid exchange frequency to 12.0 per cell from 5.9 in untreated cells, raised Ag-positive nucleolus organizer regions to 2.5 per cell from 0.95, and reduced large pericentromeric heterochromatin variants on chromosomes 1 and 9; the authors read this as chromatin decondensation (PMID 23221144). A 2009 report combined it with copper and cadmium ions in lymphocyte culture (PMID 19359734). These are chromatin measures in blood cells, not prostate measures. The abstracts do not discuss whether a higher exchange frequency has any significance beyond chromatin decondensation.

Participants / model
Lymphocytes or leukocytes from older people
Treatment
Peptide in cell culture; concentration and cell source not stated here
Follow-up
not stated in the source
Study design
Cell-culture chromatin and chromosome studies
Funding
not stated in the source

Human cells with no human treatment. The cell source and peptide concentration for the 2012 study are not stated here.

Read the original source

Does Prostamax support the prostate?

Only in tissue culture. Prostate explants from rats grew faster with the peptide in culture, and there is no prostate disease model, no prostate measure in any living animal and no human data for the peptide. The clinical reports in the prostate field that the searches found belong to Prostatilen, a different product.

Sellers promote Prostamax for prostate support. The claim is supported only as faster growth of prostate explants from rats in culture, in one 2006 report. A PubMed search on 10 October 2026 for prostamax or prostomax returned 5 records: the explant study and the four human-cell chromatin papers. The same search with prostate terms returned 1 record, the explant study.

In the records reviewed there is no animal model of prostate disease, no measure of prostate size, PSA or urinary function after the peptide, no human dose, no human pharmacokinetics and no human safety data. The same search with clinical trial or randomized controlled trial publication types returned 0 records, and ClinicalTrials.gov returned no study for Prostamax or for a KEDP prostate peptide.

The only human clinical reports in the prostate field that the searches found are for Prostatilen, a different product, and they are not evidence about this peptide.

Every result on this page is for the synthetic tetrapeptide. No PubMed record describes a Cytomax or Cytogen retail product, so nothing here is cited to those product lines.

2006 explant study: prostate explants from young and aged rats

Cell study

Zakutskiĭ AN et al. Adv Gerontol. 2006;19:93-6. PMID 17152728.

A 2006 Russian-language report used synthetic cardiogen, bronchogen, prostamax, and pancragen on organotypic explants of heart, lung, prostate, and pancreas from 3-week-old and 18-month-old rats. At 0.05 ng/ml each peptide stimulated growth in its matching tissue culture compared with control explants in all groups. The abstract reports no prostate size, hormone, or disease endpoint. This is the only study of the peptide in prostate tissue, and growth of prostate tissue in culture is not a benefit endpoint.

Participants / model
Prostate explants from young (3-week) and aged (18-month) rats
Treatment
Peptide in culture medium at 0.05 ng/ml
Follow-up
not stated in the source
Study design
Organotypic explant culture, Russian-language report
Funding
not stated in the source

Explant growth is not a benefit endpoint, and the abstract reports no prostate size, hormone or disease measure.

Read the original source
PubMed: 5 records, one in prostate tissue, no clinical trial

PubMed search record

PubMed searches run 10 October 2026: prostamax[tiab] OR prostomax[tiab]; (prostamax OR prostomax OR "Lys-Glu-Asp-Pro" OR KEDP) AND (prostate OR prostatic OR BPH OR prostatitis OR hyperplasia); the same query with clinical trial or randomized controlled trial publication types. ClinicalTrials.gov, openFDA Drugs@FDA and DailyMed queries, run the same day.

A PubMed search for prostamax[tiab] OR prostomax[tiab] returned 5 records: the 2006 explant study and the four human-cell chromatin papers. A search for (prostamax OR prostomax OR "Lys-Glu-Asp-Pro" OR KEDP) AND (prostate OR prostatic OR BPH OR prostatitis OR hyperplasia) returned 1 record, the explant study. The same query with clinical trial or randomized controlled trial publication types returned 0 records. ClinicalTrials.gov returned no study for Prostamax or for a KEDP prostate peptide. openFDA Drugs@FDA and DailyMed return no product named Prostamax. In the records reviewed there is no animal model of prostate disease, no measure of prostate size, PSA, or urinary function after the peptide, no human dose, no human pharmacokinetics, and no human safety data.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Search run on 10 October 2026
Study design
Dated literature and registry search
Funding
not stated in the source

An absence finding as of 10 October 2026, not proof that no unpublished work exists.

Read the original source

How is Prostamax thought to work?

No mechanism for any prostate effect is established. In human blood cells in culture the peptide decondensed chromatin, and in rat prostate explants it stimulated growth. No pharmacokinetic data exist.

The laboratory observations are chromatin changes in blood cells from older people. Prostamax decondensed pericentromeric chromatin of chromosome 1, shifted chromatin denaturation endotherms of lymphocytes, raised Ag-positive nucleolus organizer regions and, in a 2012 study, raised the sister chromatid exchange frequency, which the authors read as chromatin decondensation.

These are blood cell measures and say nothing about the prostate. The explant study shows faster growth of rat prostate tissue in culture. The abstracts give no pharmacokinetic data, and no human dose or exposure was found.

Human blood cells in culture: chromatin decondensation and sister chromatid exchange

Cell study

Dzhokhadze TA et al. Georgian Med News. 2012(212):76-82. PMID 23221144.

A 2004 abstract found that Prostamax, with Epithalon and Livagen, decondensed pericentromeric chromatin of chromosome 1 in leukocytes from subjects aged 75 to 88 (PMID 15085253). A 2004 Russian-language study found that prostamax shifted chromatin denaturation endotherms of human lymphocytes by 2.9 and 1.0 degrees C (PMID 15612551). A 2012 Russian-language study in cells from people aged 75 to 86 reports that Prostamax raised the sister chromatid exchange frequency to 12.0 per cell from 5.9 in untreated cells, raised Ag-positive nucleolus organizer regions to 2.5 per cell from 0.95, and reduced large pericentromeric heterochromatin variants on chromosomes 1 and 9; the authors read this as chromatin decondensation (PMID 23221144). A 2009 report combined it with copper and cadmium ions in lymphocyte culture (PMID 19359734). These are chromatin measures in blood cells, not prostate measures. The abstracts do not discuss whether a higher exchange frequency has any significance beyond chromatin decondensation.

Participants / model
Lymphocytes or leukocytes from older people
Treatment
Peptide in cell culture; concentration and cell source not stated here
Follow-up
not stated in the source
Study design
Cell-culture chromatin and chromosome studies
Funding
not stated in the source

Human cells with no human treatment. The cell source and peptide concentration for the 2012 study are not stated here.

Read the original source
2006 explant study: prostate explants from young and aged rats

Cell study

Zakutskiĭ AN et al. Adv Gerontol. 2006;19:93-6. PMID 17152728.

A 2006 Russian-language report used synthetic cardiogen, bronchogen, prostamax, and pancragen on organotypic explants of heart, lung, prostate, and pancreas from 3-week-old and 18-month-old rats. At 0.05 ng/ml each peptide stimulated growth in its matching tissue culture compared with control explants in all groups. The abstract reports no prostate size, hormone, or disease endpoint. This is the only study of the peptide in prostate tissue, and growth of prostate tissue in culture is not a benefit endpoint.

Participants / model
Prostate explants from young (3-week) and aged (18-month) rats
Treatment
Peptide in culture medium at 0.05 ng/ml
Follow-up
not stated in the source
Study design
Organotypic explant culture, Russian-language report
Funding
not stated in the source

Explant growth is not a benefit endpoint, and the abstract reports no prostate size, hormone or disease measure.

Read the original source

What is known about the safety of Prostamax?

No human safety data exist for Prostamax: the searches found no human dose, pharmacokinetics or treatment study. No study addresses whether stimulating prostate tissue growth is desirable or safe in men with prostate disease, and a 2012 abstract reports a higher sister chromatid exchange frequency in treated human cells without discussing its significance.

A PubMed search on 10 October 2026 found no human treatment study of Prostamax, so there is no human dose, no human pharmacokinetics and no human safety data. No study addresses whether stimulating prostate tissue growth is desirable or safe in men with prostate disease, and the one study in prostate tissue measured explant growth only.

A 2012 Russian-language study reports that Prostamax raised the sister chromatid exchange frequency in cells from older people to 12.0 per cell from 5.9 in untreated cells. The abstracts do not discuss whether a higher exchange frequency has any significance beyond chromatin decondensation.

Prostatilen and Prostataget are different products, so any safety statement made about them does not carry over to this tetrapeptide.

PubMed: 5 records, one in prostate tissue, no clinical trial

PubMed search record

PubMed searches run 10 October 2026: prostamax[tiab] OR prostomax[tiab]; (prostamax OR prostomax OR "Lys-Glu-Asp-Pro" OR KEDP) AND (prostate OR prostatic OR BPH OR prostatitis OR hyperplasia); the same query with clinical trial or randomized controlled trial publication types. ClinicalTrials.gov, openFDA Drugs@FDA and DailyMed queries, run the same day.

A PubMed search for prostamax[tiab] OR prostomax[tiab] returned 5 records: the 2006 explant study and the four human-cell chromatin papers. A search for (prostamax OR prostomax OR "Lys-Glu-Asp-Pro" OR KEDP) AND (prostate OR prostatic OR BPH OR prostatitis OR hyperplasia) returned 1 record, the explant study. The same query with clinical trial or randomized controlled trial publication types returned 0 records. ClinicalTrials.gov returned no study for Prostamax or for a KEDP prostate peptide. openFDA Drugs@FDA and DailyMed return no product named Prostamax. In the records reviewed there is no animal model of prostate disease, no measure of prostate size, PSA, or urinary function after the peptide, no human dose, no human pharmacokinetics, and no human safety data.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Search run on 10 October 2026
Study design
Dated literature and registry search
Funding
not stated in the source

An absence finding as of 10 October 2026, not proof that no unpublished work exists.

Read the original source
2006 explant study: prostate explants from young and aged rats

Cell study

Zakutskiĭ AN et al. Adv Gerontol. 2006;19:93-6. PMID 17152728.

A 2006 Russian-language report used synthetic cardiogen, bronchogen, prostamax, and pancragen on organotypic explants of heart, lung, prostate, and pancreas from 3-week-old and 18-month-old rats. At 0.05 ng/ml each peptide stimulated growth in its matching tissue culture compared with control explants in all groups. The abstract reports no prostate size, hormone, or disease endpoint. This is the only study of the peptide in prostate tissue, and growth of prostate tissue in culture is not a benefit endpoint.

Participants / model
Prostate explants from young (3-week) and aged (18-month) rats
Treatment
Peptide in culture medium at 0.05 ng/ml
Follow-up
not stated in the source
Study design
Organotypic explant culture, Russian-language report
Funding
not stated in the source

Explant growth is not a benefit endpoint, and the abstract reports no prostate size, hormone or disease measure.

Read the original source
Human blood cells in culture: chromatin decondensation and sister chromatid exchange

Cell study

Dzhokhadze TA et al. Georgian Med News. 2012(212):76-82. PMID 23221144.

A 2004 abstract found that Prostamax, with Epithalon and Livagen, decondensed pericentromeric chromatin of chromosome 1 in leukocytes from subjects aged 75 to 88 (PMID 15085253). A 2004 Russian-language study found that prostamax shifted chromatin denaturation endotherms of human lymphocytes by 2.9 and 1.0 degrees C (PMID 15612551). A 2012 Russian-language study in cells from people aged 75 to 86 reports that Prostamax raised the sister chromatid exchange frequency to 12.0 per cell from 5.9 in untreated cells, raised Ag-positive nucleolus organizer regions to 2.5 per cell from 0.95, and reduced large pericentromeric heterochromatin variants on chromosomes 1 and 9; the authors read this as chromatin decondensation (PMID 23221144). A 2009 report combined it with copper and cadmium ions in lymphocyte culture (PMID 19359734). These are chromatin measures in blood cells, not prostate measures. The abstracts do not discuss whether a higher exchange frequency has any significance beyond chromatin decondensation.

Participants / model
Lymphocytes or leukocytes from older people
Treatment
Peptide in cell culture; concentration and cell source not stated here
Follow-up
not stated in the source
Study design
Cell-culture chromatin and chromosome studies
Funding
not stated in the source

Human cells with no human treatment. The cell source and peptide concentration for the 2012 study are not stated here.

Read the original source

Why does Prostamax sit in D tier?

Prostamax has exactly one paper in prostate tissue, a rat explant study, and four chromatin papers in blood cells. There is no animal in vivo study, no disease model and no human data for the peptide, and the only clinical reports in the prostate field are for a different product.

The peptide has a PubChem sequence record, one explant study in prostate tissue and four chromatin papers in human blood cells. It has no animal in vivo study and no prostate disease model, so the record is thinner than a coherent preclinical profile in the claimed system.

A PubMed search on 10 October 2026 found no clinical trial and no human data for the peptide, and the human clinical reports in the prostate field belong to Prostatilen, which is a different product.

2006 explant study: prostate explants from young and aged rats

Cell study

Zakutskiĭ AN et al. Adv Gerontol. 2006;19:93-6. PMID 17152728.

A 2006 Russian-language report used synthetic cardiogen, bronchogen, prostamax, and pancragen on organotypic explants of heart, lung, prostate, and pancreas from 3-week-old and 18-month-old rats. At 0.05 ng/ml each peptide stimulated growth in its matching tissue culture compared with control explants in all groups. The abstract reports no prostate size, hormone, or disease endpoint. This is the only study of the peptide in prostate tissue, and growth of prostate tissue in culture is not a benefit endpoint.

Participants / model
Prostate explants from young (3-week) and aged (18-month) rats
Treatment
Peptide in culture medium at 0.05 ng/ml
Follow-up
not stated in the source
Study design
Organotypic explant culture, Russian-language report
Funding
not stated in the source

Explant growth is not a benefit endpoint, and the abstract reports no prostate size, hormone or disease measure.

Read the original source
Human blood cells in culture: chromatin decondensation and sister chromatid exchange

Cell study

Dzhokhadze TA et al. Georgian Med News. 2012(212):76-82. PMID 23221144.

A 2004 abstract found that Prostamax, with Epithalon and Livagen, decondensed pericentromeric chromatin of chromosome 1 in leukocytes from subjects aged 75 to 88 (PMID 15085253). A 2004 Russian-language study found that prostamax shifted chromatin denaturation endotherms of human lymphocytes by 2.9 and 1.0 degrees C (PMID 15612551). A 2012 Russian-language study in cells from people aged 75 to 86 reports that Prostamax raised the sister chromatid exchange frequency to 12.0 per cell from 5.9 in untreated cells, raised Ag-positive nucleolus organizer regions to 2.5 per cell from 0.95, and reduced large pericentromeric heterochromatin variants on chromosomes 1 and 9; the authors read this as chromatin decondensation (PMID 23221144). A 2009 report combined it with copper and cadmium ions in lymphocyte culture (PMID 19359734). These are chromatin measures in blood cells, not prostate measures. The abstracts do not discuss whether a higher exchange frequency has any significance beyond chromatin decondensation.

Participants / model
Lymphocytes or leukocytes from older people
Treatment
Peptide in cell culture; concentration and cell source not stated here
Follow-up
not stated in the source
Study design
Cell-culture chromatin and chromosome studies
Funding
not stated in the source

Human cells with no human treatment. The cell source and peptide concentration for the 2012 study are not stated here.

Read the original source
PubMed: 5 records, one in prostate tissue, no clinical trial

PubMed search record

PubMed searches run 10 October 2026: prostamax[tiab] OR prostomax[tiab]; (prostamax OR prostomax OR "Lys-Glu-Asp-Pro" OR KEDP) AND (prostate OR prostatic OR BPH OR prostatitis OR hyperplasia); the same query with clinical trial or randomized controlled trial publication types. ClinicalTrials.gov, openFDA Drugs@FDA and DailyMed queries, run the same day.

A PubMed search for prostamax[tiab] OR prostomax[tiab] returned 5 records: the 2006 explant study and the four human-cell chromatin papers. A search for (prostamax OR prostomax OR "Lys-Glu-Asp-Pro" OR KEDP) AND (prostate OR prostatic OR BPH OR prostatitis OR hyperplasia) returned 1 record, the explant study. The same query with clinical trial or randomized controlled trial publication types returned 0 records. ClinicalTrials.gov returned no study for Prostamax or for a KEDP prostate peptide. openFDA Drugs@FDA and DailyMed return no product named Prostamax. In the records reviewed there is no animal model of prostate disease, no measure of prostate size, PSA, or urinary function after the peptide, no human dose, no human pharmacokinetics, and no human safety data.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Search run on 10 October 2026
Study design
Dated literature and registry search
Funding
not stated in the source

An absence finding as of 10 October 2026, not proof that no unpublished work exists.

Read the original source

Studies and sources

PubChem: Prostamax identity

Chemical identity record

National Library of Medicine. PubChem compound record CID 9848296.

PubChem lists Prostamax as CID 9848296, C20H33N5O9, molecular weight 487.5, CAS 473578-47-1, with a systematic name that reads Lys-Glu-Asp-Pro. The same sequence appears in a 2012 abstract about the oligopeptide bioregulator Prostamax (Lys-Glu-Asp-Pro, PMID 23221144), and the group's 2022 table lists Prostomax (KEDP) for regulation of prostatic functions and cites a European patent.

Participants / model
Chemical identity, not a clinical population
Treatment
Defined synthetic peptide
Follow-up
Not applicable
Study design
NLM chemical record
Funding
not stated in the source

A defined tetrapeptide record.

Read the original source
2022 table: spelling Prostomax, and a different prostate dipeptide, Prostataget

Narrative review

Khavinson V et al. Int J Mol Sci. 2022;23(14). PMID 35887081.

The group's 2022 table spells the peptide Prostomax; the abstracts spell it Prostamax. The same table lists a different prostate peptide, Prostataget (DR), a dipeptide. None of the 5 records returned by the search below uses the Prostomax spelling, so it appears to be a table spelling only. Prostatilen, which has clinical papers of its own, is a different product.

Participants / model
Not a clinical population
Treatment
Not applicable
Follow-up
Not applicable
Study design
Review table
Funding
not stated in the source

Naming warning only. Prostatilen is a polypeptide preparation isolated from cattle prostate, and its 1991 Russian-language clinical reports (PMID 1823682, PMID 1823683, PMID 2058122) are for that extract, not for the synthetic tetrapeptide. Those reports are not evidence about Prostamax and are not described on this page.

Read the original source
2006 explant study: prostate explants from young and aged rats

Cell study

Zakutskiĭ AN et al. Adv Gerontol. 2006;19:93-6. PMID 17152728.

A 2006 Russian-language report used synthetic cardiogen, bronchogen, prostamax, and pancragen on organotypic explants of heart, lung, prostate, and pancreas from 3-week-old and 18-month-old rats. At 0.05 ng/ml each peptide stimulated growth in its matching tissue culture compared with control explants in all groups. The abstract reports no prostate size, hormone, or disease endpoint. This is the only study of the peptide in prostate tissue, and growth of prostate tissue in culture is not a benefit endpoint.

Participants / model
Prostate explants from young (3-week) and aged (18-month) rats
Treatment
Peptide in culture medium at 0.05 ng/ml
Follow-up
not stated in the source
Study design
Organotypic explant culture, Russian-language report
Funding
not stated in the source

Explant growth is not a benefit endpoint, and the abstract reports no prostate size, hormone or disease measure.

Read the original source
Human blood cells in culture: chromatin decondensation and sister chromatid exchange

Cell study

Dzhokhadze TA et al. Georgian Med News. 2012(212):76-82. PMID 23221144.

A 2004 abstract found that Prostamax, with Epithalon and Livagen, decondensed pericentromeric chromatin of chromosome 1 in leukocytes from subjects aged 75 to 88 (PMID 15085253). A 2004 Russian-language study found that prostamax shifted chromatin denaturation endotherms of human lymphocytes by 2.9 and 1.0 degrees C (PMID 15612551). A 2012 Russian-language study in cells from people aged 75 to 86 reports that Prostamax raised the sister chromatid exchange frequency to 12.0 per cell from 5.9 in untreated cells, raised Ag-positive nucleolus organizer regions to 2.5 per cell from 0.95, and reduced large pericentromeric heterochromatin variants on chromosomes 1 and 9; the authors read this as chromatin decondensation (PMID 23221144). A 2009 report combined it with copper and cadmium ions in lymphocyte culture (PMID 19359734). These are chromatin measures in blood cells, not prostate measures. The abstracts do not discuss whether a higher exchange frequency has any significance beyond chromatin decondensation.

Participants / model
Lymphocytes or leukocytes from older people
Treatment
Peptide in cell culture; concentration and cell source not stated here
Follow-up
not stated in the source
Study design
Cell-culture chromatin and chromosome studies
Funding
not stated in the source

Human cells with no human treatment. The cell source and peptide concentration for the 2012 study are not stated here.

Read the original source
PubMed: 5 records, one in prostate tissue, no clinical trial

PubMed search record

PubMed searches run 10 October 2026: prostamax[tiab] OR prostomax[tiab]; (prostamax OR prostomax OR "Lys-Glu-Asp-Pro" OR KEDP) AND (prostate OR prostatic OR BPH OR prostatitis OR hyperplasia); the same query with clinical trial or randomized controlled trial publication types. ClinicalTrials.gov, openFDA Drugs@FDA and DailyMed queries, run the same day.

A PubMed search for prostamax[tiab] OR prostomax[tiab] returned 5 records: the 2006 explant study and the four human-cell chromatin papers. A search for (prostamax OR prostomax OR "Lys-Glu-Asp-Pro" OR KEDP) AND (prostate OR prostatic OR BPH OR prostatitis OR hyperplasia) returned 1 record, the explant study. The same query with clinical trial or randomized controlled trial publication types returned 0 records. ClinicalTrials.gov returned no study for Prostamax or for a KEDP prostate peptide. openFDA Drugs@FDA and DailyMed return no product named Prostamax. In the records reviewed there is no animal model of prostate disease, no measure of prostate size, PSA, or urinary function after the peptide, no human dose, no human pharmacokinetics, and no human safety data.

Participants / model
Records reviewed, not a population
Treatment
Not applicable
Follow-up
Search run on 10 October 2026
Study design
Dated literature and registry search
Funding
not stated in the source

An absence finding as of 10 October 2026, not proof that no unpublished work exists.

Read the original source

Why is Prostamax in D tier?

D fits a compound with exactly one paper in prostate tissue, a rat explant study, and four chromatin papers in blood cells. There is no animal in vivo study, no prostate disease model and no human data for the peptide, and the only clinical reports in the prostate field are for a different product.